The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.

Kielbasa, William; Tesfaye, Eshetu; Luffer-Atlas, Debra; Mitchell, Malcolm I; Turik, Michael A

Kielbasa, William; Tesfaye, Eshetu; Luffer-Atlas, Debra; Mitchell, Malcolm I; Turik, Michael A.

Affiliation

Kielbasa W; Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA, wkielbasa@lilly.com.

Eur J Clin Pharmacol ; 69(12): 2011-9, 2013 Dec.

Article in En | MEDLINE | ID: mdl-23955175

Subject(s)

Adrenergic Uptake Inhibitors/pharmacokinetics; Liver Diseases/blood; Morpholines/pharmacokinetics; Phenylethyl Alcohol/analogs & derivatives; Renal Insufficiency/blood; Adrenergic Uptake Inhibitors/blood; Adult; Aged; Female; Humans; Male; Middle Aged; Morpholines/blood; Phenylethyl Alcohol/blood; Phenylethyl Alcohol/pharmacokinetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Phenylethyl Alcohol / Morpholines / Adrenergic Uptake Inhibitors / Renal Insufficiency / Liver Diseases Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google